Myriad Genetics to Present at the UBS Global Life Sciences Conference on September 26, 2005

SALT LAKE CITY, Sept. 20, 2005 -- Myriad Genetics, Inc. (Nasdaq: MYGN), announced today that its President and CEO, Peter Meldrum, is scheduled to present an overview of the Company at the UBS Global Life Sciences Conference, at 12:00 noon Eastern time on September 26, 2005, at the Grand Hyatt New York Hotel in New York City.

A live audio webcast of this presentation will be available online and can be accessed through a link on Myriad's home page at www.myriad.com. The presentation will be archived on the Myriad site for a limited time, under the Investors tab, beginning approximately three hours after the presentation.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.